Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 results on April 30, 2026, highlighting accelerating clinical adoption of its Nociscan platform. The company achieved a 196% year-over-year increase in scan volumes (Q1 2026 vs. Q1 2025) and a 64% sequential growth from Q4 2025, driven by new account activations and deeper utilization at existing sites. These results underscore the growing acceptance of Nociscan, which uses biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, aiming to improve treatment success rates.
The Nociscan platform addresses a significant market need: approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain, representing a potential $2 billion market opportunity for technologies that provide objective evaluation of discogenic pain. Aclarion's growth is supported by early payer adoption in the U.K., where Nociscan has been reimbursed by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K. The company also launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. In the U.S., Aclarion continues engagement with payers through its Nociscan Reimbursement Program to establish coverage pathways, as detailed on their website.
On the clinical front, Aclarion is advancing the CLARITY randomized trial, designed to validate the clinical utility of Nociscan in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. Additionally, seven ongoing clinical trials and multiple investigator-initiated real world evidence trials are underway to support reimbursement discussions and potential local coverage decisions by commercial insurers. The company also strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products, bringing its total to 64 issued and pending patents worldwide, reinforcing its competitive moat and scaling capabilities.
Financially, Aclarion enters this growth phase with a strong balance sheet. As of March 31, 2026, the company held $19.0 million in cash with no outstanding debt and a clean capital structure. With 2,444,871 common shares outstanding (2,882,371 on a fully diluted basis), this represents approximately $6.60 per share in cash. The company also announced a $2.5 million share repurchase program this week. Based on current operating plans, Aclarion believes its existing cash resources are sufficient to fund operations into the second half of 2027. "Q1 represents a clear inflection for Aclarion. Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market, with nearly 6 million lumbar MRIs performed annually in the U.S. alone," said Brent Ness, Chief Executive Officer of Aclarion. For more information, visit the latest news at Aclarion Newsroom.
